Protease-activated receptors (PARs)—biology and role in cancer invasion and metastasis

Cancer and Metastasis Reviews

Volumn 34, Issue 4, 2015, Pages 775-796

  Wojtukiewicz, Marek Z ^a,b   Hempel, Dominika ^a,b   Sierko, Ewa ^a,b   Tucker, Stephanie C ^c   Honn, Kenneth V ^c,d,e  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Regional Comprehensive Cancer Center in Bialystok   (Poland)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Cancer invasion; Metastasis; Microenvironment; PAR 1; PAR 2; Thrombin; Tissue factor

Indexed keywords

INTEGRIN; MATRIX METALLOPROTEINASE; PROTEINASE ACTIVATED RECEPTOR; THROMBIN; THROMBOPLASTIN; TRYPSIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; MELANOMA; METASTASIS; MICROBIOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THROMBOCYTE; TUMOR INVASION; ENZYME ACTIVATION; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

BLOOD PLATELETS; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, PAR-1; RECEPTOR, PAR-2; THROMBIN; THROMBOPLASTIN; TUMOR MICROENVIRONMENT;

EID: 84958921542     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-015-9599-4     Document Type: Article

References (254)

1. Trousseau, A. (1865). Phlegmasia dolens. Clinique Medicale de l’Hotel-Dieu de Paris, 3, 490–515.
2. Zacharski, L. R., Henderson, W. G., Rickles, F. R., Forman, W. B., Cornell, C. J., Forcier, R. J., et al. (1984). Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer, 53(10), 2046–2052.
3. Altinbas, M., Coskun, H., Er, O., Ozkan, M., Eser, B., Unal, A., et al. (2004). A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis, 2, 1266–1271.
4. Nierodzik, M. L., & Karpatkin, S. (2006). Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell, 10(5), 355–362.
5. Zigler, M., Kamiya, T., Brantley, E. C., Villares, G. J., & Bar-Eli, M. (2011). PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Research, 71(21), 6561–6566.
6. Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014). Platelets and cancer: a casual or causal relationship: revisited. Cancer and Metastasis Reviews, 33(1), 231–269.
7. Rieser, P. (1967). The insulin-like action of pepsin and pepsinogen. Acta Endocrinologica, 54, 375–379.
8. Carney, D. H., & Cunningham, D. D. (1997). Initiation of chick cell division by trypsin action at the cell surface. Nature, 268(5621), 602–606.
9. Wojtukiewicz, M. Z., Sierko, E., Zacharski, L. R., Zimnoch, L., Kudryk, B., & Kisiel, W. (2003). Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Seminars in Thrombosis and Hemostasis, 29(3), 291–300.
10. Wojtukiewicz, M. Z., Zacharski, L. R., Ruciñska, M., Zimnoch, L., Jaromin, J., Rózañska-Kudelska, M., et al. (1999). Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thrombosis and Haemostasis, 82(6), 1659–1662.
11. Sierko, E., Wojtukiewicz, M. Z., Zimnoch, L., Thorpe, P. E., Brekken, R. A., & Kisiel, W. (2011). Co-localization of prothrombin fragment F1 + 2 and VEGF-R2-bound VEGF in human colon cancer. Anticancer Research, 31(3), 843–847.
12. Vu, T. K., Hung, D. T., Wheaton, V. I., & Coughlin, S. R. (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 64(6), 1057–10568.
13. Vu, T. K. H., Wheaton, V. I., Hung, D. T., & Coughlin, S. R. (1991). Domains specifying thrombin-receptor interaction. Nature, 353(6345), 674–677.
14. Wojtukiewicz, M. Z., Tang, D. G., Ben-Josef, E., Renaud, C., Walz, D. A., & Honn, K. V. (1995). Solid tumor cells express functional “tethered ligand” thrombin receptor. Cancer Research, 55(3), 698–704.
15. Austin, K. M., Covic, L., & Kuliopulos, A. (2013). Matrix metalloproteases and PAR1 activation. Blood, 121(3), 431–439.
16. Yang, E., Boire, A., Agarwal, A., Nguyen, N., O'Callaghan, K., Tu, P., et al. (2009). Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Research, 69(15), 6223–6231.
17. Sedda, S., Marafini, I., Caruso, R., Pallone, F., & Monteleone, G. (2014). Proteinase activated-receptors-associated signaling in the control of gastric cancer. World Journal of Gastroenterology, 20(34), 11977–11984.
18. Fujimoto, D., Hirono, Y., Goi, T., Katayama, K., & Yamaguchi, A. (2008). Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Research, 28(2A), 847–854.
19. Suen, J. Y., Barry, G. D., Lohman, R. J., Halili, M. A., Cotterell, A. J., Le, G. T., et al. (2012). Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). British Journal of Pharmacology, 165(5), 1413–1423.
20. Sevigny, L. M., Zhang, P., Bohm, A., Lazarides, K., Perides, G., Covic, L., et al. (2011). Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proceedings of the National Academy of Sciences of the United State of America, 108(20), 8491–8496.
21. Villares, G. J., Zigler, M., Wang, H., Melnikova, V. O., Wu, H., Friedman, R., et al. (2008). Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Research, 68, 9078–9086.
22. Asanuma, K., Wakabayashi, H., Hayashi, T., Okuyama, N., Seto, M., Matsumine, A., et al. (2004). Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology, 67(2), 166–173.
23. Coughlin, S. R. (2005). Protease-activated receptors in hemostasis, thrombosis and vascular biology. Journal of Thrombosis and Haemostasis, 3, 1800–1814.
24. Ramachandran, R., Noorbakhsh, F., Defea, K., & Hollenberg, M. D. (2012). Targeting proteinase-activated receptors: therapeutic potential and challenges. Nature Reviews Drug Discovery, 11(1), 69–86.
25. Rasmussen, U. B., Vouret-Craviari, V., Jallat, S., Schlesinger, Y., Pagers, G., Pavirani, A., et al. (1991). cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Letters, 288(1–2), 123–128.
26. Vu, T. K., Hung, D. T., Wheaton, V. I., & Coughlin, S. R. (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 64(6), 1057–1068.
27. Nystedt, S., Emilsson, K., Wahlestedt, C., & Sundelin, J. (1994). Molecular cloning of a potential novel proteinase activated receptor. Proceedings of the National Academy of Sciences of the United State of America, 91(20), 9208–9212.
28. Xu, W. F., Andersen, H., Whitmore, T. E., Presnell, S. R., Yee, D. P., Ching, A., et al. (1998). Cloning and characterization of human protease-activated receptor 4. Proceedings of the National Academy of Sciences of the United State of America, 95(12), 6642–6646.
29. Ossovskaya, V. S., & Bunnett, N. W. (2004). Protease-activated receptors: contribution to physiology and disease. Physiological Reviews, 84(2), 579–621.
30. Lin, H., Liu, A. P., Smith, T. H., & Trejo, J. (2013). Cofactoring and dimerization of proteinase-activated receptors. Pharmacological Reviews, 65(4), 1198–1213.
31. Junge, C. E., Lee, C. J., Hubbard, K. B., Zhang, Z., Olson, J. J., Hepler, J. R., et al. (2004). Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. Experimental Neurology, 188(1), 94–103.
32. Arora, P., Ricks, T. K., & Trejo, J. (2007). Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. Journal of Cell Science, 120(6), 921–928.
33. Lin, H., & Trejo, J. (2013). Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits β-arrestin-mediated endosomal signaling. Journal of Biological Chemistry, 288, 11203–11215.
34. McLaughlin, J. N., Patterson, M. M., & Malik, A. B. (2007). Protease-activated receptor3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proceedings of the National Academy of Sciences of the United State of America, 104(13), 5662–5667.
35. O’Brien, P. J., Prevost, N., Molino, M., Hollinger, M. K., Woolkalis, M. J., & Woulfe, D. S. (2000). Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin cleaved PAR1. The Journal of Biology and Chemistry, 275(18), 13502–13509.
36. Leger, A. J., Jacques, S. L., Badar, J., Kaneider, N. C., Derian, C. K., Andrade-Gordon, P., et al. (2006). Blocking the protease-activated receptor 1–4 heterodimer in platelet-mediated thrombosis. Circulation, 113(9), 1244–1254.
37. Madhusudhan, T., Wang, H., Straub, B. K., Gröne, E., Zhou, Q., Shahzad, K., et al. (2012). Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood, 119(3), 874–883.
38. Albrektsen, T., Sorensen, B. B., Hjorto, G. M., Fleckner, J., Rao, L. V., & Petersen, L. C. (2007). Transcriptional program induced by factor VIIa tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. Journal of Thrombosis and Haemostasis, 5(8), 1588–1597.
39. Agarwal, A., Covic, L., Sevigny, L. M., Kaneider, N. C., Lazarides, K., Azabdaftari, G., et al. (2008). Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Molecular Cancer Therapeutics, 7, 2746–2757.
40. van den Berg, Y. W., Osanto, S., Reitsma, P. H., & Versteeg, H. H. (2012). The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood, 119(4), 924–932.
41. Wojtukiewicz, M. Z., Tang, D. G., Nelson, K. K., Walz, D. A., Diglio, C. A., & Honn, K. V. (1992). Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thrombosis Research, 68(3), 233–45.
42. Wojtukiewicz, M. Z., Tang, D. G., Ciarelli, J. J., Nelson, K. K., Walz, D. A., Diglio, C. A., et al. (1993). Thrombin increases the metastatic potential of tumor cells. International Journal of Cancer, 54(5), 793–806.
43. Zhu, Q., Luo, J., Wang, T., Ren, J., Hu, K., & Wu, G. (2012). The activation of protease-activated receptor 1 mediates proliferation and invasion of nasopharyngeal carcinoma cells. Oncology Reports, 28(1), 255–261.
44. Otsuki, T., Fujimoto, D., Hirono, Y., Goi, T., & Yamaguchi, A. (2014). Thrombin conducts epithelial mesenchymal transition via protease activated receptor 1 in human gastric cancer. International Journal of Oncology, 45, 2287–2294.
45. Fujimoto, D., Hirono, Y., Goi, T., Katayama, K., Matsukawa, S., & Yamaguchi, A. (2010). The activation of Proteinase-Activated Receptor-1 (PAR1) mediates gastric cancer cell proliferation and invasion. Biomedical Central Cancer, 10, 443–458.
46. Fujimoto, D., Hirono, Y., Goi, T., Katayama, K., Matsukawa, S., & Yamaguchi, A. (2013). The activation of proteinase-activated receptor-1 (PAR1) promotes gastric cancer cell alteration of cellular morphology related to cell motility and invasion. International Journal of Oncology, 42(2), 565–573.
47. Arora, P., Cuevas, B. D., Russo, A., Johnson, G. L., & Trejo, J. (2008). Persistent transactivation of EGFR and ErbB2/HER2 by protease activated receptor-1 promotes breast carcinoma cell invasion. Oncogene, 27(32), 4434–4445.
48. Nierodzik, M. L., Chen, K., Takeshita, K., Li, J. J., Huang, Y. Q., Feng, X. S., et al. (1998). Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood, 92(10), 3694–3700.
49. Chen, H. T., Tsou, H. K., Tsai, C. H., Kuo, C. C., Chiang, Y. K., Chang, C. H., et al. (2010). Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway. Journal of Cellular Physiology, 223(3), 737–745.
50. Shi, X., Gangadharan, B., Brass, L. F., Ruf, W., & Mueller, B. M. (2004). Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Molecular Cancer Research, 2(7), 395–402.
51. D'Asti, E., Kool, M., Pfister, S. M., & Rak, J. (2014). Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk. Journal of Thrombosis and Haemostasis, 12(11), 1838–1849.
52. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., & Kuliopulos, A. (2005). PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell, 120(3), 303–313.
53. Xie, L., Duan, Z., Liu, C., Zheng, Y., & Zhou, J. (2015). Protease-activated receptor 2 agonist increases cell proliferation and invasion of human pancreatic cancer cells. Experimental and Therapeutic Medicine, 9(1), 239–244.
54. Shimamoto, R., Sawada, T., Uchima, Y., Inoue, M., Kimura, K., Yamashita, Y., et al. (2004). A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. International Journal of Oncology, 24(6), 1401–1406.
55. Kaufmann, R., Schafberg, H., & Nowak, G. (1998). Proteinase-activated receptor-2-mediated signaling and inhibition of DNA synthesis in human pancreatic cancer cells. International Journal of Pancreatology, 24(2), 97–102.
56. Zhou, J., Xie, L., Li, X., Chen, X. Y., Chen, L., Zheng, Y. M., et al. (2010). Promotion of protease-activated receptor 2 agonists on cell invasion and metastasis of esophageal cancer cell EC109. Shi Jie Hua Ren Xiao Hua Za Zhi, 18(13), 1313–1319.
57. Xie, L., Zheng, Y., Li, X., Zhao, J., Chen, X., Chen, L., et al. (2012). Enhanced proliferation of human hepatoma cells by PAR-2 agonists via the ERK/AP-1pathway. Oncology Reports, 28(5), 1665–1672.
58. Kaufmann, R., Oettel, C., Horn, A., Halbhuber, K. J., Eitner, A., Krieg, R., et al. (2009). Met receptor tyrosine kinase transactivation is involved in proteinase activated receptor 2 mediated hepatocellular carcinoma cell invasion. Carcinogenesis, 30(9), 1487–1496.
59. Kaufmann, R., Hascher, A., Mussbach, F., Henklein, P., Katenkamp, K., Westermann, M., et al. (2012). Proteinase-activated receptor 2 (PAR(2)) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level. Histochemistry and Cell Biology, 138(6), 913–924.
60. Soreide, K., Janssen, E. A., Körner, H., & Baak, J. P. (2006). Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. The American Journal of Pathology, 209(2), 147–156.
61. Nishibori, M., Mori, S., & Takahashi, H. K. (2005). Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell. Journal of Pharmacological Sciences, 97(1), 25–30.
62. Jikuhara, A., Yoshii, M., Iwagaki, H., Mori, S., Nishibori, M., & Tanaka, N. (2003). MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. Life Science, 73(22), 2817–2829.
63. Sánchez-Hernández, P. E., Ramirez-Dueñas, M. G., Albarran-Somoza, B., García-Iglesias, T., del Toro-Arreola, A., Franco-Topete, R., et al. (2008). Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation. Gynecologic Oncology, 108(1), 19–26.
64. Al-Eryani, K., Cheng, J., Abé, T., Maruyama, S., Yamazaki, M., Babkair, H., et al. (2015). Protease-activated receptor 2 modulates proliferation and invasion of oral squamous cell carcinoma cells. Human Pathology, 46(7), 991–999.
65. Kaufmann, R., Patt, S., Zieger, M., Kraft, R., & Nowak, G. (1999). Presence of the proteinase-activated receptor-2 (PAR-2) in human brain tumor cells--trypsin- and SLIGRL-induced calcium response in primary cultured meningiomas. Cancer Letters, 139(1), 109–113.
66. Su, S., Li, Y., Luo, Y., Sheng, Y., Su, Y., Padia, R. N., et al. (2009). Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene, 28(34), 3047–3057.
67. Jiang, X., Bailly, M. A., Panetti, T. S., Cappello, M., Konigsberg, W. H., & Bromberg, M. E. (2004). Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. Journal of Thrombosis and Haemostasis, 2(1), 93–101.
68. Morris, D. R., Ding, Y., Ricks, T. K., Gullapalli, A., Wolfe, B. L., & Trejo, J. (2006). Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Research, 66(1), 307–314.
69. Hjortoe, G. M., Petersen, L. C., Albrektsen, T., Sorensen, B. B., Norby, P. L., Mandal, S. K., et al. (2004). Tissue factor–factor VIIa specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood, 103(8), 3029–3037.
70. Lin, Z. M., Zhao, J. X., Duan, X. N., Zhang, L. B., Ye, J. M., Xu, L., et al. (2014). Effects of tissue factor, PAR-2 and MMP-9 expression on human breast cancer cell line MCF-7 invasion. Asian Pacific Journal of Cancer Prevention, 15(2), 643–646.
71. Li, X., & Tai, H. H. (2014). Thromboxane A2 receptor-mediated release of matrix metalloproteinase-1 (MMP-1) induces expression of monocyte chemoattractant protein-1 (MCP-1) by activation of protease-activated receptor 2 (PAR2) in A549 human lung adenocarcinoma cells. Molecular Carcinogenesis, 53, 650–666.
72. Carneiro-Lobo, T. C., Lima, M. T., Mariano-Oliveira, A., Dutra-Oliveira, A., Oba-Shinjo, S. M., Marie, S. K., et al. (2014). Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin-8 in human astrocytoma patients. Oncology Reports, 31(2), 679–686.
73. Dutra-Oliveira, A., Monteiro, R. Q., & Mariano-Oliveira, A. (2012). Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines. Biochemical and Biophysical Research Communications, 421(2), 221–227.
74. D'Andrea, M. R., Derian, C. K., Santulli, R. J., & Andrade-Gordon, P. (2001). Differential expression of protease activated receptors-1 and −2 in stromal fibroblasts of normal, benign, and malignant human tissues. American Journal of Pathology, 158, 2031–2041.
75. Bar-Shavit, R., Turm, H., Salah, Z., Maoz, M., Cohen, I., Weiss, E., et al. (2011). PAR1 plays a role in epithelial malignancies: transcriptional regulation and novel signaling pathway. International Union of Biochemistry and Molecular Biology Life, 63(6), 397–402.
76. Tellez, C. S., Davis, D. W., Prieto, V. G., Gershenwald, J. E., Johnson, M. M., McCarty, M. F., et al. (2007). Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease activated receptor-1 expression during melanoma progression. Journal of Investigative Dermatology, 127, 387–393.
77. Yin, Y. J., Salah, Z., Grisaru-Granovsky, S., Cohen, I., Even-Ram, S., Maoz, M., et al. (2003). Human protease-activated receptor-1 expression in malignant epithelia: a role in invasiveness. Ateriosclerosis, Thrombosis, and Vascular Biology, 23, 940–944.
78. Uzunoglu, F. G., Yavari, N., Bohn, B. A., Nentwich, M. F., Reeh, M., Pantel, K., et al. (2013). C-X-C motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC. Lung Cancer, 81(1), 123–129.
79. Uzunoglu, F. G., Kolbe, J., Wikman, H., Güngör, C., Bohn, B. A., Nentwich, M. F., et al. (2013). VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma. Annals of Oncology, 24(5), 1282–1290.
80. Gieseler, F., Ungefroren, H., Settmacher, U., Hollenberg, M. D., & Kaufmann, R. (2013). Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Communication and Signaling. doi:10.1186/1478-811X-11-86.
81. Riewald, M., Petrovan, R. J., Donner, A., Mueller, B. M., & Ruf, W. (2002). Activation of endothelial cell protease activated receptor-1 by the protein C pathway. Science, 296(5574), 1880–1888.
82. Cleary, D. B., Trumbo, T. A., & Maurer, M. C. (2002). Protease-activated receptor 4-like peptides bind to thrombin through an optimized interaction with the enzyme active site surface. Archives of Biochemistry and Biophysics, 403(2), 179–188.
83. Riewald, M., & Ruf, W. (2001). Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proceedings of the National Academy of Sciences of the United State of America, 98(14), 7742–7747.
84. Larsen, K. S., Ostergaard, H., Olsen, O. H., Bjelke, J. R., Ruf, W., & Petersen, L. C. (2010). Engineering of substrate selectivity for tissue factor.factor VIIa complex signaling through protease-activated receptor 2. Journal of Biological Chemistry, 285(26), 19959–19966.
85. Martin, C. B., Mahon, G. M., Klinger, M. B., Kay, R. J., Symons, M., Der, C. J., et al. (2001). The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene, 20(16), 1953–1963.
86. Stalheim, L., Ding, Y., Gullapalli, A., Paing, M. M., Wolfe, B. L., Morris, D. R., et al. (2005). Multiple independent functions of arrestins in regulation of protease activated receptor-2 signaling and trafficking. Molecular Pharmacology, 67(1), 1–10.
87. Trivedi, V., Boire, A., Tchernychev, B., Kaneider, N. C., Leger, A. J., O'Callaghan, K., et al. (2009). Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell, 137(2), 332–343.
88. Stavenuiter, F., & Mosnier, L. O. (2014). Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity. Blood, 124(23), 3480–3489.
89. Soh, U. J., Dores, M. R., Chen, B., & Trejo, J. (2010). Signal transduction by protease-activated receptors. British Journal of Pharmacology, 160(2), 191–203.
90. Gullapalli, A., Wolfe, B. L., Griffin, C. T., Magnuson, T., & Trejo, J. (2006). An essential role for SNX1 in lysosomal sorting protease-activated receptor-1: evidence for retromer, Hrs and Tsg101 independent functions of sorting nexins. Molecular Biology of the Cell, 17(3), 12228–12238.
91. Shapiro, M. J., Weiss, E. J., & Faruqi, T. R. (2000). Coughlin SR. Protease activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. Journal of Biological Chemistry, 275(33), 25216–25221.
92. Grimsey, N., Lin, H., & Trejo, J. (2014). Endosomal signaling by protease-activated receptors. Methods in Enzymology, 535, 389–401.
93. Nesi, A., & Fragai, M. (2007). Substrate specificities of matrix metalloproteinase 1 in PAR-1 exodomain proteolysis. Chembiochem, 8(12), 1367–1369.
94. Booden, M. A., Ekert, L., Der, C. J., & Trejo, J. (2004). Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Molecular Cell. Biology, 24(5), 1990–1999.
95. Sierko, E., Wojtukiewicz, M. Z., & Kisiel, W. (2007). The role of tissue factor pathway inhibitor-2 in cancer biology. Seminars in Thrombosis and Hemostasis, 33(7), 653–659.
96. Sierko, E., Zawadzki, R. J., & Wojtukiewicz, M. Z. (2002). Tissue factor pathway inhibitors. Polski Merkuriusz Lekarski, 13(73), 66–69.
97. Ünlü, B., & Versteeg, H. H. (2014). Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor? Thrombosis Research, 133(Suppl 2), S76–84.
98. Wojtukiewicz, M. Z., Sierko, E., & Rak, J. (2004). Contribution of the hemostatic system to angiogenesis in cancer. Seminars in Thrombosis and Hemostasis, 30(1), 5–20.
99. Schaffner, F., & Ruf, W. (2009). Tissue factor and PAR2 signaling in the tumor microenvironment. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(12), 1999–2004.
100. Yu, J. L., May, L., Lhotak, V., et al. (2005). Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood, 105(4), 1734–1741.
101. Regina, S., Valentin, J. B., Lachot, S., Lemarié, E., Rollin, J., & Gruel, Y. (2009). Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clinical Chemistry, 55(10), 1834–1842.
102. Fan, L., Yotov, W. V., Zhu, T., Esmailzadeh, L., Joyal, J. S., Sennlaub, F., et al. (2005). Tissue factor enhances protease-activated receptor-2-mediated factor VIIa cell proliferative properties. Journal of Thrombosis and Haemostasis, 3(5), 1056–1063.
103. Ott, I., Weigand, B., Michl, R., Seitz, I., Sabbari-Erfani, N., Neumann, F. J., et al. (2005). Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation, 111(3), 349–355.
104. van den Berg, Y. W., van den Hengel, L. G., Myers, H. R., Ayachi, O., Jordanova, E., Ruf, W., et al. (2009). Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proceedings of the National Academy of Sciences of the United State of America, 106(46), 19497–19502.
105. Hobbs, J. E., Zakarija, A., Cundiff, D. L., et al. (2007). Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thrombosis Research, 120(suppl 2), S13–S21.
106. Yokota, N., Zarpellon, A., Chakrabarty, S., Bogdanov, V. Y., Gruber, A., Castellino, F. J., et al. (2014). Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. Journal of Thrombosis and Haemostasis, 12(1), 71–81.
107. Mueller, B. M., Reisfeld, R. A., Edgington, T. S., & Ruf, W. (1992). Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proceedings of the National Academy of Sciences of the United State of America, 89(24), 11832–11836.
108. Conn, E. M., Madsen, M. A., Cravatt, B. F., Ruf, W., Deryugina, E. I., & Quigley, J. P. (2008). Cell surface proteomicsidentifies molecules functionally linked to tumor cell intravasation. Journal of Biological Chemistry, 283(39), 26518–26527.
109. Versteeg, H. H., Schaffner, F., Kerver, M., Petersen, H. H., Ahamed, J., Felding-Habermann, B., et al. (2008). Inhibition of tissue factor signaling suppresses tumor growth. Blood, 111(1), 190–199.
110. Schaffner, F., Versteeg, H. H., Schillert, A., Yokota, N., Petersen, L. C., Mueller, B. M., et al. (2010). Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood, 116(26), 6106–6113.
111. Svensson, K. J., Kucharzewska, P., Christianson, H. C., Sköld, S., Löfstedt, T., Johansson, M. C., et al. (2011). Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proceedings of the National Academy of Sciences of the United State of America, 108(32), 13147–13152.
112. Poole, D. P., Amadesi, S., Veldhuis, N. A., Abogadie, F. C., Lieu, T., Darby, W., et al. (2013). Protease-activated receptor 2 (PAR2) protein and transient receptor potential vanilloid 4 (TRPV4) protein coupling is required for sustained inflammatory signaling. Journal of Biology and Chemistry, 288(8), 5790–5802.
113. Fiorio Pla, A., & Munaron, L. (2014). Functional properties of ion channels and transporters in tumour vascularization. Philosofical Transaction of the Royal Society of London. Series B. Biological Sciences. doi:10.1098/rstb.2013.0103.
114. Everaerts, W., Nilius, B., & Owsianik, G. (2010). The vanilloid transient receptor potential channel TRPV4: from structure to disease. Progress in Biophycis and Molecular Biology, 103(1), 2–17.
115. Magnus, N., Garnier, D., & Rak, J. (2010). Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood, 116(5), 815–818.
116. Koizume, S., Jin, M. S., Miyagi, E., Hirahara, F., Nakamura, Y., Piao, J. H., et al. (2006). Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Research, 66(19), 9453–9460.
117. Dilly, A. K., Ekambaram, P., Guo, Y., Cai, Y., Tucker, S. C., Fridman, R., et al. (2013). Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-κB. International Journal of Cancer, 133(8), 1784–1791.
118. Camerer, E., Qazi, A. A., Duong, D., Cornelissen, I., Advincula, R., & Coughlin, S. R. (2004). Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood, 104(2), 397–401.
119. Zacharski, L. R., et al. (1995). Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Thrombosis and Haemostasis, 73(5), 793–797.
120. Tsopanoglou, N. E., & Maragoudakis, M. E. (2004). Role of thrombin in angiogenesis and tumor progression. Seminars in Thrombosis and Hemostasis, 30(1), 63–69.
121. Palumbo, J. S., Kombrinck, K. W., Drew, A. F., Grimes, T. S., Kiser, J. H., Degen, J. L., et al. (2000). Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood, 96(10), 3302–3309.
122. Yuan, L., & Liu, X. (2015). Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism. Molecular Medicine Reports, 11(4), 2449–2458.
123. Wojtukiewicz, M.Z., Ciarelli, J.J., Walz, D.A., Honn, K.V. (1990). Thrombin enhances cancer cell expression of an integrin receptor and increases adhesion. 81st Annual Meeting of the Americsan Association for Cancer Research, Washington, Proceedings of AACR, 31, Abstract 476.
124. Wojtukiewicz, M.Z., Ciarelli, J.J., Snyder, D.A., Nelson, K.K., Walz, D.A., Honn, K.V. (1990). Increased tumor cell adhesiveness and experimental metastasis following exposure to alpha-thrombin, its precursor and analogues. American Cancer Society Michigan Division Inc., 1990 Cancer Research Conference, Ypsilanti, MI, USA, Poster 22
125. Wojtukiewicz, M.Z., Ciarelli, J.J., Snyder, D., Nelson, K.K., Walz, D.A., Honn, K.V. (1990). Thrombin increases tumor cell adhesiveness via a non-proteolytic pathway. First Regional Meeting of the American Society for Cell Biology, Chicago, IL, USA, 1990, Abstract 91.
126. Wojtukiewicz, M. Z., Tang, D. G., Nelson, K. K., Walz, D. A., Diglio, C. A., & Honn, K. V. (1992). Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thrombosis Research, 68, 233–245.
127. Wojtukiewicz, M. Z., Tang, D. G., Ciarelli, J. J., Nelson, K. K., Walz, D. A., Diglio, C. A., et al. (1993). Thrombin increases the metastatic potential of tumor cells. International Journal of Cancer, 54, 793–806.
128. Nierodzik, M. L., Kajumo, F., & Karpatkin, S. (1992). Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Research, 52(12), 3267–3272.
129. Guo, A. M., Liu, X., Al-Wahab, Z., Maddippati, K. R., Ali-Fehmi, R., Scicli, A. G., et al. (2011). Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival. Cancer Chemotherapy and Pharmacology, 68(5), 1273–1283.
130. Mahajan, V. B., Pai, K. S., Lau, A., & Cunningham, D. D. (2000). Creatine kinase, an ATP-generating enzyme, is required for thrombin receptor signaling to the cytoskeleton. Proceedings of the National Academy of Science of the United State of America, 97(22), 12062–12067.
131. Nierodzik, M., Plotkin, A., Kajumo, F., & Karpatkin, S. (1991). Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. Journal of Clinical Investigation, 87(1), 229–236.
132. Hu, L., Lee, M., Campbell, W., Perez-Soler, R., & Karpatkin, S. (2004). Role of endogenous thrombin in tumor implantation, seeding and spontaneous metastasis. Blood, 104(9), 2746–2751.
133. Liu, C. Y., Nossel, H. L., & Kaplan, K. L. (1979). The binding of thrombin by fibrin. Journal of Biological Chemistry, 254(20), 10421–10425.
134. Queiroz, K. C., Shi, K., Duitman, J., Aberson, H. L., Wilmink, J. W., van Noesel, C. J., et al. (2014). Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. International Journal of Cancer, 135(10), 2294–2304.
135. Krishnamoorthy, S., & Honn, K. V. (2008). Eicosanoids in tumor progression and metastasis. Subcellular Biochemistry, 49, 145–168.
136. Tucker, S. C., & Honn, K. V. (2013). Emerging targets in lipid-based therapy. Biochemical Pharmacology, 85(5), 673–688.
137. Nie, D., Tang, K., Szekeres, K., Trikha, M., & Honn, K. V. (2000). The role of eicosanoids in tumor growth and metastasis. Ernst Schering Research Foundation Workshop Journal, 31, 201–217.
138. Coughlin, S. R. (2000). Thrombin signalling and protease-activated receptors. Nature, 407(6801), 258–264.
139. Zania, P., Kritikou, S., Flordellis, C. S., Maragoudakis, M. E., & Tsopanoglou, N. E. (2006). Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. Journal of Pharmacology and Experimental Therapeutics, 318, 246–254.
140. Konstantoulaki, M., Kouklis, P., & Malik, A. (2003). Protein kinase C modifications of VE-cadherin, p120, and β-catenin contribute to endothelial barrier dysregulation induced by thrombin. Americal Journal of Physiology. Lung Cellular and Molecular Physiology, 285(2), 434–442.
141. Huang, Y. Q., Li, J. J., Hu, L., Lee, M., & Karpatkin, S. (2002). Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood, 99(5), 1646–1650.
142. Tang, D. G., Diglio, C. A., & Honn, K. V. (1993). 12(S)-HETE-induced microvascular endothelial cell retraction results from PKC-dependent rearrangement of cytoskeletal elements and alpha V beta 3 integrins. Prostaglandins, 45(3), 249–67.
143. Tang, D. G., Chen, Y. Q., Diglio, C. A., & Honn, K. V. (1993). Protein kinase C-dependent effects of 12(S)-HETE on endothelial cell vitronectin receptor and fibronectin receptor. Journal of Cell Biology, 121(3), 689–704.
144. Tang, K., Cai, Y., Joshi, S., Tovar, E., Tucker, S. C., Maddipati, K. R., et al. (2015). Convergence of eicosanoid and integrin biology: 12-lipoxygenase seeks a partner. Molecular Cancer, 14, 111.
145. Rezaie, A. R. (2011). The occupancy of endothelial protein C receptor by its ligand modulates the par-1 dependent signaling specificity of coagulation proteases. International Union of Biochemistry and Molecular Biology Life, 63(6), 390–396.
146. Uchiba, M., Okajima, K., Oike, Y., Ito, Y., Fukudome, K., Isobe, H., et al. (2004). Activated Protein C Induces Endothelial Cell Proliferation by Mitogen-Activated Protein Kinase Activation In Vitro and Angiogenesis In Vivo. Circulation Research, 95(1), 34–41.
147. Gramling, M. W., Beaulieu, L. M., & Church, F. C. (2010). Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction. Experimental Cell Research, 316(3), 314–328.
148. Horowitz, N. A., Blevins, E. A., Miller, W. M., Perry, A. R., Talmage, K. E., Mullins, E. S., et al. (2011). Thrombomodulin is a determinant of metastasis through a mechanism linked to thethrombin binding domain but not the lectin-like domain. Blood, 118(10), 2889–2895.
149. Burzaco, J., Conde, M., Parada, L. A., Zugaza, J. L., Dehaye, J. P., & Marino, A. (2013). ATP antagonizes thrombin-induced signal transduction through 12(S)-HETE and cAMP. PLoS One, 8(6), e67117. doi:10.1371/journal.pone.0067117.
150. Holinstat, M., Voss, B., Bilodeau, M. L., McLaughlin, J. N., Cleator, J., & Hamm, H. E. (2006). PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation. Journal of Biological Chemistry, 281(36), 26665–26674.
151. Sierko, E., & Wojtukiewicz, M. Z. (2007). Inhibition of platelet function: does it offer a chance of better cancer progression control? Seminars in Thrombosis and Hemostasis, 33(7), 712–721.
152. Nieswandt, B., Hafner, M., Echtenacher, B., & Mannel, D. (1999). Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Research, 59(6), 1295–1300.
153. Huang, Z., Miao, X., Luan, Y., Zhu, L., Kong, F., Lu, Q., Pernow, J., et al. (2015). PAR1-stimulated platelet releasate promotes angiogenic activities of endothelial progenitor cells more potently than PAR4-stimulated platelet releasate. Thrombosis and Haemostasis, 13(3), 465–476.
154. Even-Ram, S., Uziely, B., Cohen, P., Grisaru-Granovsky, S., Maoz, M., Ginzburg, Y., et al. (1998). Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Medicine, 4(8), 909–914.
155. Borensztajn, K. S., Bijlsma, M. F., Groot, A. P., Brüggemann, L. W., Versteeg, H. H., Reitsma, P. H., et al. (2007). Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation. Experimental Cell Research, 313(12), 2622–2633.
156. Li, S. M., Jiang, P., Xiang, Y., Wang, W. W., Zhu, Y. C., Feng, W. Y., et al. (2015). Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squamous cell carcinoma. Dongwuxue Yanjiu, 35(5), 420–425.
157. Liao, M., Tong, P., Zhao, J., Zhang, Y., Li, Z., Wang, J., et al. (2012). Prognostic value of matrix metalloproteinase-1/ proteinase-activated receptor-1 signaling axis in hepatocellular carcinoma. Pathology and Oncology Research, 18(2), 397–403.
158. Bäumer, N., Krause, A., Köhler, G., Lettermann, S., Evers, G., Hascher, A., et al. (2014). Proteinase-Activated Receptor 1 (PAR1) regulates leukemic stem cell functions. PLoS One, 9(4), e94993. doi:10.1371/journal.pone.0094993.
159. Zain, J., Huang, Y. Q., Feng, X., Nierodzik, M. L., Li, J. J., & Karpatkin, S. (2000). Concentration-dependent dual effect of thrombin on impaired growth/ apoptosis or mitogenesis in tumor cells. Blood, 95(10), 3133–3138.
160. Trejo, J., Connolly, A. J., & Coughlin, S. R. (1996). The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. Journal of Biological Chemistry, 271(35), 21536–21541.
161. Yin, Y. J., Salah, Z., Grisaru-Granovsky, S., Cohen, I., Even-Ram, S., Maoz, M., et al. (2003). Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. Federation of American Societies for Experimental Biology Journal, 17(2), 163–174.
162. Mußbach, F., Henklein, P., Westermann, M., Settmacher, U., Böhmer, F. D., & Kaufmann, R. (2014). Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation. Journal of Cancer Research and Clinical Oncology, 141(5), 813–825.
163. Even-Ram, S. C., Maoz, M., Pokroy, E., Reich, R., Katz, B. Z., Gutwein, P., et al. (2001). Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. Journal of Biological Chemistry, 276(14), 10952–10962.
164. Bai, S. Y., Xu, N., Chen, C., Song, Y. L., Hu, J., & Bai, C. X. (2014). Integrin αvβ5 as a biomarker for the assessment of non-small cell lung cancer metastasis and overall survival. Clinical Respiratory Journal. doi:10.1111/crj.12163.
165. Trikha, M., Timar, J., Zacharek, A., Nemeth, J. A., Cai, Y., Dome, B., et al. (2002). Role for beta3 integrins in human melanoma growth and survival. International Journal of Cancer, 101(2), 156–167.
166. Rásó, E., Tóvári, J., Tóth, K., Paku, S., Trikha, M., Honn, K. V., et al. (2001). Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase- and PKC-mediated serine phosphorylation events in melanoma cells. Thrombosis and Haemostasis, 85(6), 1037–1042.
167. Dvorak, H. F. (1986). Tumors: wounds that do not heal. The New England Journal of Medicine, 315(26), 1650–1659.
168. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Natural Medicine, 1(1), 27–31.
169. Griffin, C. T., Srinivasan, Y., Zheng, Y. W., Huang, W., & Coughlin, S. R. (2001). A role for thrombin receptor signaling in endothelial cells during embryonic development. Science, 293(5535), 1666–1670.
170. Tsopanoglou, N. E., & Maragoudakis, M. E. (1999). On the mechanism of thrombin-induced angiogenesis: Potentiation of vascular endothelial growth factor activity on endothelial cells by upregulation of its receptors. Journal of Biological Chemistry, 274(34), 23969–23976.
171. Richard, D. E., Vouret-Craviari, V., & Pouysségur, J. (2001). Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene, 20(13), 1556–1562.
172. Yamahata, H., Takeshima, H., Kuratsu, J., Sarker, K. P., Tanioka, K., Wakimaru, N., et al. (2002). The role of thrombin in the neo-vascularization of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor. International Journal of Oncology, 20(5), 921–928.
173. Xie, Q., Bao, X., Chen, Z. H., Xu, Y., Keep, R. F., Muraszko, K. M., et al. (2016). Role of Protease-Activated Receptor-1 in Glioma Growth. Acta Neurochirurgica. Supplement, 121, 355–360.
174. Krishnamoorthy, S., Jin, R., Cai, Y., Maddipati, K. R., Nie, D., Pagès, G., et al. (2010). 12-Lipoxygenase and the regulation of hypoxia-inducible factor in prostate cancer cells. Experimental Cell Research, 316(10), 1706–1715.
175. Ekambaram, P., Lambiv, W., Cazzolli, R., Ashton, A. W., & Honn, K. V. (2011). The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Reviews, 30(3–4), 397–408.
176. Honn, K. V. (1983). Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clinical and Experimental Metastasis, 1(2), 103–114.
177. Honn, K. V., Tang, D. G., Grossi, I. M., Renaud, C., Duniec, Z. M., Johnson, C. R., et al. (1994). Enhanced endothelial cell retraction mediated by 12(S)-HETE: a proposed mechanism for the role of platelets in tumor cell metastasis. Experimental Cell Research, 210(1), 1–9.
178. Honn, K. V., Grossi, I. M., Fitzgerald, L. A., Umbarger, L. A., Diglio, C. A., et al. (1988). Lipoxygenase products regulate IRGpIIb/IIIa receptor mediated adhesion of tumor cells to endothelial cells, subendothelial matrix and fibronectin. Proceedings of the Society for Experimental Biology and Medicine, 189(1), 130–135.
179. Honn, K. V., Tang, D. G., & Chen, Y. Q. (1992). Platelets and cancer metastasis: more than an epiphenomenon. Seminars in Thrombosis and Hemostasis, 18(4), 392–415.
180. Steinert, B. W., Tang, D. G., Grossi, I. M., Umbarger, L. A., & Honn, K. V. (1993). Studies on the role of platelet eicosanoid metabolism and integrin alpha IIb beta 3 in tumor-cell-induced platelet aggregation. International Journal of Cancer, 54, 92–101.
181. Chen, Y. Q., Hagmann, W., & Honn, K. V. (1997). Regulation of 12(S)-HETE production in tumor cells. Advances in Experimental Medicine and Biology, 400A, 159–166.
182. Krishnamoorthy, S., & Honn, K. V. (2011). Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment. Cancer Metastasis Reviews, 30(3–4), 613–618.
183. Pidgeon, G. P., Lysaght, J., Krishnamoorthy, S., Reynolds, J. V., O'Byrne, K., Nie, D., et al. (2007). Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Reviews, 26(3–4), 503–524.
184. Pidgeon, G. P., Tang, K., Cai, Y. L., Piasentin, E., & Honn, K. V. (2003). Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Cancer Research, 63(14), 4258–4267.
185. Rásó, E., Döme, B., Somlai, B., Zacharek, A., Hagmann, W., Honn, K. V., et al. (2004). Molecular identification, localization and function of platelet-type 12-lipoxygenase in human melanoma progression, under experimental and clinical conditions. Melanoma Research, 14(4), 245–250.
186. Timar, J., Bazaz, R., Tang, D. G., Kimler, V., Taylor, J. D., & Honn, K. V. (1997). Post-translational regulation of surface integrin expression in tumor cells by 12(S)-HETE. Advances in Experimental Medicine and Biology, 400B, 757–763.
187. Holinstat, M., Boutaud, O., Apopa, P. L., Vesci, J., Bala, M., Oates, J. A., et al. (2011). Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(2), 435–42.
188. Thomas, C. P., Morgan, L. T., Maskrey, B. H., Murphy, R. C., Kühn, H., Hazen, S. L., et al. (2010). Phospholipid-esterified eicosanoids are generated in agonist-activated human platelets and enhance tissue factor-dependent thrombin generation. The Journal of Biology and Chemistry, 285(10), 6891–6903.
189. Pereira, L., Mariadason, J. M., Hannan, R. D., & Dhillon, A. S. (2015). Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer. Frontiers in Oncology. doi:10.3389/fonc.2015.00013.
190. Du, X., Wang, S., Lu, J., Cao, Y., Song, N., Yang, T., et al. (2011). Correlation between MMP1-PAR1 axis and clinical outcome of primary gallbladder carcinoma. Japanese Journal of Clinical Oncology, 41(9), 1086–1093.
191. Malaquin, N., Vercamer, C., Bouali, F., Martien, S., Deruy, E., Wernert, N., et al. (2013). Senescent fibroblasts enhance early skin carcinogenic events via a paracrine MMP-PAR-1 axis. PLoS One, 8(5), e63607.
192. Fujimoto, D., Hirono, Y., Goi, T., Katayama, K., Hirose, K., & Yamaguchi, A. (2006). Expression of protease activated receptor-2 (PAR-2) in gastric cancer. Journal of Surgical Oncology, 93(2), 139–144.
193. Olejar, T., Vetvicka, D., Zadinova, M., Pouckova, P., Kukal, J., & Jezek, P. (2014). Dual role of host Par2 in a murine model of spontaneous metastatic B16 melanoma. Anticancer Research, 34(7), 3511–3515.
194. Shi, K., Queiroz, K. C., Roelofs, J. J., van Noesel, C. J., Richel, D. J., & Spek, C. A. (2014). Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. The American Journal of Pathology, 234(3), 398–409.
195. Zheng, Y. M., Xie, L. Q., Li, X., Zhao, J. Y., Chen, X. Y., Chen, L., et al. (2009). Effect of ERK/AP-1 signaling pathway on proliferation of hepatoma cells induced by PAR-2 agonists. Zhonghua Yi Xue Za Zhi, 89, 3116–3121.
196. Libert, C. (2003). Inflammation: A nervous connection. Nature, 421(6921), 328–329.
197. Kwong, K., Nassenstein, C., de Garavilla, L., Meeker, S., & Undem, B. J. (2010). Thrombin and trypsin directly activate vagal C-fibres in mouse lung via protease-activated receptor-1. Journal of Physiology, 588(Pt 7), 1171–1177.
198. Grant, A., Amadesi, S., Bunnett, N.W. (2007). Protease-Activated Receptors: Mechanisms by Which Proteases Sensitize TRPV Channels to Induce Neurogenic Inflammation and Pain. In: Liedtke WB, Heller S, editors. TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades. Boca Raton (FL): CRC Press; 2007. Chapter 31. Frontiers in Neuroscience.
199. Gregus, A. M., Doolen, S., Dumlao, D. S., Buczynski, M. W., Takasusuki, T., Fitzsimmons, B. L., et al. (2012). Spinal 12-lipoxygenase-derived hepoxilin A3 contributes to inflammatory hyperalgesia via activation of TRPV1 and TRPA1 receptors. Proceedings of the National Academy of Sciences of the United State of America, 109(17), 6721–6726.
200. Amadesi, S., Cottrell, G. S., Divino, L., Chapman, K., Grady, E. F., Bautista, F., et al. (2006). Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice. Journal of Physiology, 575(Pt 2), 555–571.
201. Hoogerwerf, W. A., Zou, L., Shenoy, M., Sun, D., Micci, M. A., Lee-Hellmich, H., et al. (2001). The proteinase-activated receptor 2 is involved in nociception. Journal of Neuroscience, 21(22), 9036–9042.
202. Smith, H. S. (2006). Arachidonic acid pathways in nociception. Journal of Supportive Oncology, 4(6), 277–287.
203. Shim, W. S., Tak, M. H., Lee, M. H., Kim, M., Kim, M., Koo, J. Y., et al. (2007). TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. Journal of Neuroscience, 27(9), 2331–2337.
204. Vinuesa, A. G., Sancho, R., García-Limones, C., Behrens, A., ten Dijke, P., Calzado, M. A., et al. (2012). Vanilloid receptor-1 regulates neurogenic inflammation in colon and protects mice from colon cancer. Cancer Research, 72(7), 1705–1716.
205. Nie, D., Che, M., Zacharek, A., Qiao, Y., Li, L., Li, X., et al. (2004). Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. American Journal of Pathology, 164(2), 429–439.
206. Potter, S. R., & Partin, A. W. (2000). The significance of perineural invasion found on needle biopsy of the prostate: implications for definitive therapy. Reviews in Urology, 2(2), 87–90.
207. Liebig, C., Ayala, G., Wilks, J. A., Berger, D. H., & Albo, D. (2009). Perineural invasion in cancer: a review of the literature. Cancer, 115(15), 3379–3391.
208. de Garavilla, L., Vergnolle, N., Young, S. H., Ennes, H., Steinhoff, M., Ossovskaya, V. S., et al. (2001). Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. British Journal of Pharmacology, 133(7), 975–987.
209. Graziottin, A., & Murina, F. (2011). How Vulvodynia Originates: the Pathophysiology of Vulvar Pain. In Clinical Management of Vulvodynia: Tips and Tricks (pp. 39–52). Italia: Springer-Verlag.
210. Nyirjesy, P. (2001). Chronic vulvovaginal candidiasis. American Family Physician, 63(4), 697–702.
211. Schouten, M., van't Veer, C., Roelofs, J. J., Levi, M., & van der Poll, T. (2012). Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study. Critical Care, 16(6), R238.
212. Kager, L. M., Wiersinga, W. J., Roelofs, J. J., van 't Veer, C., & van der Poll, T. (2014). Deficiency of protease-activated receptor-1 limits bacterial dissemination during severe Gram-negative sepsis (melioidosis). Microbes Infection, 16(2), 171–174.
213. Lan, R. S., Stewart, G. A., Goldie, R. G., & Henry, P. J. (2004). Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice. American Journal of Physiology. Lung Cellular and Molecular Physiology, 286(2), L388–98.
214. Antoniak, S., & Mackman, N. (2014). Coagulation, protease-activated receptors, and viral myocarditis. Journal of Cardiovascular Translational Research, 7(2), 203–211.
215. Antoniak, S., & Mackman, N. (2014). Multiple roles of the coagulation protease cascade during virus infection. Blood, 123(17), 2605–2613.
216. Kauffman, H. F., Tomee, J. F., van de Riet, M. A., Timmerman, A. J., & Borger, P. (2000). Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production. Journal of Allergy and Clinical Immunology, 105(6 Pt 1), 1185–1193.
217. Grab, D. J., Garcia-Garcia, J. C., Nikolskaia, O. V., Kim, Y. V., Brown, A., Pardo, C. A., et al. (2009). Protease activated receptor signaling is required for African trypanosome traversal of human brain microvascular endothelial cells. PLoS Neglected Tropical Diseases, 3(7), e479.
218. de Stoppelaar, S. F., Van't Veer, C., van den Boogaard, F. E., Nieuwland, R., Hoogendijk, A. J., de Boer, O. J., et al. (2013). Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice. Thrombosis and Haemostasis, 110(3), 582–592.
219. Lourbakos, A., Potempa, J., Travis, J., D'Andrea, M. R., Andrade-Gordon, P., Santulli, R., et al. (2001). Arginine-specific protease from Porphyromonas gingivalis activates protease-activated receptors on human oral epithelial cells and induces interleukin-6 secretion. Infection and Immunity, 69(8), 5121–5130.
220. Inaba, H., Sugita, H., Kuboniwa, M., Iwai, S., Hamada, M., Noda, T., et al. (2014). Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation. Cellular Microbiology, 16(1), 131–145.
221. Koziel, J., & Potempa, J. (2013). Protease-armed bacteria in the skin. Cell and Tissue Research, 351(2), 325–337.
222. Hoge, R., Pelzer, A., Rosenau, F., & Wilhelm, S. (2010). Weapons of a pathogen: Proteases and their role in virulence of Pseudomonas aeruginosa in Current Research. In A. Mendez Vilas (Ed.), Technology and Education Topics in Applied Microbiology and Microbial Biotechnology (Vol. 1, pp. 383–395). Badajoz: Formatex Research Center.
223. Frees, D., Brøndsted, L., & Ingmer, H. (2013). Bacterial proteases and virulence. Subcellular Biochemistry, 66, 161–192.
224. Robinson, M.W., Dalton, J.P. (2011). Cysteine Proteases of Pathogenic Organisms. Landes Bioscience.
225. Sevenich, L., & Joyce, J. A. (2014). Pericellular proteolysis in cancer. Genes and Development, 28(21), 2331–2347.
226. Klarström, E. K., Khalaf, H., Kälvegren, H., & Bengtsson, T. (2015). The role of Porphyromonas gingivalis gingipains in platelet activation and innate immune modulation. Molecular Oral Microbiology, 30(1), 62–73.
227. Carroll, I. M., & Maharshak, N. (2013). Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications. World Journal of Gastroenterology, 19(43), 7531–7543.
228. http://www.research-projects.uzh.ch/p17282.htm. Accessed 7 October 2015.
229. de Zoete, M. R., Bouwman, L. I., Keestra, A. M., & van Putten, J. P. (2011). Cleavage and activation of a Toll-like receptor by microbial proteases. Proceedings of the National Academy of Sciences of the United States of America, 108(12), 4968–4973.
230. Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., et al. (2015). Gut microbiome and anticancer immune response: really hot Shot! Cell Death and Differentiation, 22(2), 199–214.
231. Shreiner, A. B., Kao, J. Y., & Young, V. B. (2015). The gut microbiome in health and in disease. Current Opinion in Gastroenterology, 31(1), 69–75.
232. Shapira, I., Sultan, K., Lee, A., & Taioli, E. (2013). Evolving concepts: how diet and the intestinal microbiome act as modulators of breast malignancy. International Scholarly Research Notices Oncology, 2013, 693920.
233. Reinhardt, C., Bergentall, M., Greiner, T. U., Schaffner, F., Ostergren-Lundén, G., Petersen, L. C., et al. (2012). Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling. Nature, 483(7391), 627–631.
234. Cane, K., Sharp, P. J., Eagles, H. A., Eastwood, R. F., Hollamby, G. J., Kuchel, H., et al. (2008). The effects on grain quality traits of a grain serpin protein and the VPM1 segment in southern Australian wheat breeding. Australian Journal of Agricultural Research, 59, 883–890.
235. Graf, D., Di Cagno, R., Fåk, F., Flint, H. J., Nyman, M., Saarela, M., & Watzl, B. (2015). Contribution of diet to the composition of the human gut microbiota. Microbial Ecology in Health and Disease, 26, 26164. doi:10.3402/mehd.v26.26164.
236. Rose, D. J. (2014). Impact of whole grains on the gut microbiota: the next frontier for oats? British Journal of Nutrition, 112(2), S44–49.
237. White, B. A., Lamed, R., Bayer, E. A., & Flint, H. J. (2014). Biomass utilization by gut microbiomes. Annual Review of Microbiology, 68, 279–296.
238. Cooper, D. N., Martin, R. J., & Keim, N. L. (2015). Does Whole Grain Consumption Alter Gut Microbiotaand Satiety? Healthcare, 3, 364–392.
239. http://www.wheatbellyblog.com/2015/04/the-jokes-on-the-whole-grains-council. Acdessed 22 October 2015
240. Esumi, N., Fan, D., & Fidler, I. J. (1991). Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Research, 51(17), 4549–4556.
241. Macaulay, T. E., Allen, C., & Ziada, K. M. (2010). Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348. Expert Opinion on Pharmacotherapy, 11(6), 1015–1022.
242. Walz, D.A., Fenton, J.W. (1994–1995). The role of thrombin in tumor cell metastasis. Invasion Metastasis, 14(1–6), 303–308.
243. Wang, J., Boerma, M., Kulkarni, A., Hollenberg, M. D., & Hauer-Jensen, M. (2010). Activation of protease activated receptor 2 by exogenous agonist exacerbates early radiation injury in rat intestine. International Journal of Radiation Oncology Biology Physics, 77(4), 1206–1212.
244. Wang, J., Kulkarni, A., Chintala, M., Fink, L. M., & Hauer-Jensen, M. (2013). Inhibition of protease-activated receptor 1 ameliorates intestinal radiation mucositis in a preclinical rat model. International Journal of Radiation Oncology Biology Physics, 85(1), 208–214.
245. Wang, J., Zheng, H., Ou, X., Albertson, C. M., Fink, L. M., Herbert, J. M., et al. (2004). Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure. Thrombosis and Haemostasis, 2, 2027–2035.
246. Bao, Y., Hou, W., Yang, L., Kong, X., Du, M., Zheng, H., et al. (2015). Protease-Activated Receptor 2 Antagonist Potentiates Analgesic Effects of Systemic Morphine in a Rat Model of Bone Cancer Pain. Regional Anesthesia and Pain Medicine, 40(2), 158–165.
247. http://www.clinicaltrials.gov. Accessed 7 October 2015.
248. Jaber, M., Maoz, M., Kancharla, A., Agranovich, D., Peretz, T., Grisaru-Granovsky, S., et al. (2014). Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer. Cellular and Molecular Life Sciences, 71(13), 2517–2533.
249. Blackburn, J. S., Liu, I., Coon, C. I., & Brinckerhoff, C. E. (2009). A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene, 28(48), 4237–4248.
250. Massi, D., Naldini, A., Ardinghi, C., Carraro, F., Franchi, A., Paglierani, M., et al. (2005). Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Human Pathology, 36(6), 676–685.
251. Melnikova, V. O., Balasubramanian, K., Villares, G. J., Dobroff, A. S., Zigler, M., Wang, H., et al. (2009). Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanomacell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. Journal of Biological Chemistry, 284(42), 28845–28855.
252. Silini, A., Ghilardi, C., Ardinghi, C., Bernasconi, S., Oliva, P., Carraro, F., et al. (2010). Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clinical and Experimental Metastasis, 27(1), 43–53.
253. Villares, G., Zigler, M., & Bar-Eli, M. (2011). The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis—a possible therapetic target. Oncotarget, 2(1–2), 8–17.
254. Denk, A. E., Bettstetter, M., Wild, P. J., Hoek, K., Bataille, F., Dietmaier, W., et al. (2007). Loss of maspin expression contributes to a more invasive potential in malignant melanoma. Pigment Cell Research, 20(2), 112–119.